Core Insights - Altimmune, Inc. released topline results from the IMPACT Phase 2b trial of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH), a severe liver disease [1] Group 1: Trial Details - The Phase 2b trial included 212 participants with biopsy-confirmed MASH and fibrosis stages F2/F3, randomized to receive either weekly subcutaneous pemvidutide at 1.2 mg or 1.8 mg doses, or placebo for 24 weeks [2] - Treatment discontinuation rates were low, with only 9% of participants prematurely discontinuing treatment [3] Group 2: Efficacy Results - In an intent-to-treat (ITT) analysis, the proportions of participants achieving MASH resolution without worsening of fibrosis at 24 weeks were 59.1% for pemvidutide 1.2 mg, 52.1% for 1.8 mg, and 19.1% for placebo (p< 0.0001 for both doses) [3] - The effects on fibrosis improvement without worsening of MASH were 31.8% for pemvidutide 1.2 mg, 34.5% for 1.8 mg, compared to 25.9% for placebo, although these differences were not statistically significant [4] Group 3: Analyst Ratings - HC Wainwright reiterated a Buy rating for Altimmune with a price forecast of $12, believing the data supports advancing pemvidutide to Phase 3 and strengthens its case as a potential best-in-class therapy [5] - Conversely, William Blair maintained a Market Perform rating, citing "underwhelming" results and concerns about demonstrating significant fibrosis improvement at the 48-week mark [6] Group 4: Stock Performance - ALT stock is trading lower by 1.80% to $3.545 at last check [7]

RT ARK Funds (@ARK_Funds)A wave of new investors has doubled the ARK Venture Fund’s value, yet, as @PratherARK explains, our strategy remains the same: high-conviction investing, strong private company relationships, and a balanced public–private mix.ARKVX: https://t.co/FjEkAZSmy3 https://t.co/oXJUPrkU8o ...

Key Takeaways Clearfield saw robust Q2 growth with revenues hitting $47.2M, up 28% from the prior-year quarter. Strong growth in Community Broadband and a 255% surge in Large Regional Provider sales drove the revenue rise. CLFD is leveraging BEAD and E-ACAM programs, plus diverse supply chain, to support continued market expansion.Clearfield, Inc. (CLFD) reported a substantial 28% top-line improvement year over year to $47.2 million in the second quarter of 2025. The upsurge is primarily driven by healthy ...

Key Takeaways TRNO signed a 103K sq ft lease in Redondo Beach, set to begin in stages from July to October 2025. The lessee is a provider of in-space mobility; the lease runs through October 2035. In Q1 2025, TRNO's cash rents on new and renewed leases surged 34.2% with a 71.7% retention ratio.Terreno Realty (TRNO) recently announced the execution of a 103,000 square feet lease in Redondo Beach, CA. The new lease is scheduled to commence in stages between July and October 2025, and slated for expiry in Oc ...

Denmark is clawing back €232 million seized in Germany during a criminal probe of hedge fund founder Sanjay Shah as it tries to recover billions lost to the sprawling Cum-Ex tax scandal https://t.co/rpxSzcipAm ...

A ruling by the Supreme Court made on the second to last day of its term will have major implications for Planned Parenthood. The court ruled for South Carolina yesterday in its effort to defund the reproductive health care group, concluding Medicaid patients cannot sue the state over its attempt to deny Planned Parenthood Medicaid funding. The ruling was along ideological lines with all six conservative justices backing the decision and the three liberal judges opposing it.Let's bring in senior Supreme Cou ...

In Going Private, our newsletter on private markets, we look at how China's sovereign wealth fund is retreating from US private markets https://t.co/lgtgLkSULM ...

ORLANDO, Fla., June 27, 2025 (GLOBE NEWSWIRE) -- Gencor Industries, Inc. (the “Company” or “Gencor”) (NYSE American: GENC) announced today net revenue for the fourth quarter ended September 30, 2024 of $20.9 was relatively unchanged from the quarter ended September 30, 2023. Gross profit as a percentage of net revenue was 25.6% for the quarter ended September 30, 2024, compared to 31.7% for the quarter ended September 30, 2023. The higher gross profit margin in fiscal 2023 was due to increased parts sales a ...

Harvard and other top universities look to big tech and pharma companies to fill federal funding gap after Trump cuts https://t.co/jd9YSm8cqY ...

Today, the conservative majority on the United States Supreme Court ruled that states can effectively defund Planned Parenthood, the country's largest provider of reproductive health care. In a 63 ruling, the court changed federal law allowing states to unilaterally cut off all Medicaid funding from Planned Parenthood simply on the basis that it provides abortion care. Now, to be clear, abortion makes up only 3%. Abortion care only makes up 3% of Planned Parenthood services.It is a crucial 3% but it's 3%. T ...